Outcomes and Guidelines for MRI in Patients With DCIS
Melissa L. Pilewskie, MD, assistant attending physician, Memorial Sloan-Kettering Cancer Center, comments on outcomes and guidelines for MRI in patients with DCIS.
Melissa L. Pilewskie, MD, assistant attending physician, Memorial Sloan-Kettering Cancer Center, comments on outcomes and guidelines for MRI in patients with DCIS.
Clinical Pearls I
- Outcome data should support the use of any expensive test
- Data does not exist to support the routine use of MRI in DCIS patients and invasive breast cancer patients
Clinical Pearls II
- It would be beneficial to have guidelines for the appropriate use of MRI
- Currently, the use of MRI is largely dependent on the surgeon and institution
Jhaveri Compares Safety and Duration of Adjuvant CDK4/6 Inhibitors in HR+ Breast Cancer
December 22nd 2024During a Case-Based Roundtable® event, Komal Jhaveri, MD, FACP, discussed dosing and toxicity concerns with the approved CDK4/6 inhibitor regimens used in the adjuvant setting for patients with hormone receptor–positive breast cancer.
Read More
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
